🇺🇸 FDA

Company profile · Sponsor

SUTRO

SUTRO BIOPHARMA, INC.

STRO · NYSE biotech SOUTH SAN FRANCISCO, CA, USA
Pipeline
10
Drugs
0
Patents
8

Quick answer

SUTRO (STRO) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker STRO
Exchange NYSE
Company type biotech
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001382101

Pipeline (10)

Search pipeline →

  1. Luveltamab tazevibulin

    SUTRO

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  2. A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

    SUTRO

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  3. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

  4. Luveltamab tazevibulin

    SUTRO

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  5. Luveltamab tazevibulin

    SUTRO

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  6. STRO-002

    SUTRO

    Neoplasm Malignant

    phase 2 mab completed

    1 trial

  7. A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

    SUTRO

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 1 other active

    1 trial

  8. STRO-001

    SUTRO

    B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  9. STRO-002

    SUTRO

    Ovarian Cancer

    phase 1 small molecule completed

    2 trials

  10. STRO-004

    SUTRO

    Head and Neck Squamous Cell Carcinoma HNSCC

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12427201

    Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12398197

    Antibodies with engineered CH2 domains, compositions thereof and methods of using the same

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12351850

    Methods of producing full-length antibodies using E. coli

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12269801

    Modified amino acids

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12252552

    Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12226490

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12144869

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12071477

    Anti-folate receptor alpha antibody conjugated with hemiasterlins

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is SUTRO?

SUTRO (STRO) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does SUTRO sponsor?

We track 10 ClinicalTrials.gov-linked programs for SUTRO, including Luveltamab tazevibulin and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does SUTRO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.